Pre-transplant risk factors predicting post-transplant cytomegalovirus infection in liver transplant recipients

Transplant International

Volumn 20, Issue 5, 2007, Pages 419-424

  Saito, Takashi ^a,b   Egawa, Hiroto ^a   Kudo, Toyoichiro ^a   Takakura, Shunji ^a   Fujihara, Naoko ^a   Iinuma, Yoshitsugu ^a   Ichiyama, Satoshi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytomegalovirus infection; Liver transplantation; Risk factor

Indexed keywords

DNA; GANCICLOVIR;

ADULT; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; FEMALE; GRAFT INFECTION; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; LIVER FAILURE; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; INFANT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 34047237309     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00459.x     Document Type: Article

References (28)

1. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 1999; 1: 165.
2. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32: 596.
3. Seehofer D, Rayes N, Tullius SG, et al. CMV hepatitis after liver transplantation: incidence, clinical course, long-term follow-up. Liver Transpl 2002; 8: 1138.
4. Gondo H, Minematsu T, Harada M, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994; 86: 130.
5. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997; 350: 1729.
6. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854.
7. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation. 2005; 79: 85.
8. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032.
9. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73.
10. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
11. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139.
12. The TH, van der Ploeg M, van den Berg AP, Vlieger AM, van der Giessen M, van Son WJ. Direct detection of cytomegalovirus in peripheral blood leukocytes - a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992; 54: 193.
13. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005; 143: 870.
14. Egawa H, Inomata Y, Uemoto S, et al. Biliary anastomotic complications in 400 living related liver transplantations. World J Surg. 2001; 25: 1300.
15. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002; 34: 1094.
16. Tanaka N, Kimura H, Iida K, et al. Quantitative analysis of cytomegalovirus load using a real-time PCR. J Med Virol 2000; 60: 455.
17. Piiparinen H, Hockerstedt K, Lappalainen M, Suni J, Lautenschlager I. Monitoring of viral load by quantitative plasma PCR during active cytomegalovirus infection of individual liver transplant patients. J Clin Microbiol 2002; 40: 2945.
18. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185.
19. Baldanti F, Zavattoni M, Sarasini A, Gatti M, Chezzi L, Gerna G. Comparative quantification of human cytomegalovirus DNA in blood of immunocompromised patients by PCR and Murex Hybrid Capture System. Clin Diagn Virol 1997; 8: 159.
20. Griscelli F, Barrois M, Chauvin S, Lastere S, Bellet D, Bourhis JH. Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J Clin Microbiol 2001; 39: 4362.
21. Hadaya K, Wunderli W, Deffernez C, et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol 2003; 41: 3757.
22. Hebart H, Muller C, Loffler J, Jahn G, Einsele H. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17: 861.
23. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305.
24. Ikewaki J, Ohtsuka E, Kawano R, Ogata M, Kikuchi H, Nasu M. Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia- patients. J Clin Microbiol 2003; 41: 4382.
25. Singh N. Cytomegalovirus infection of liver transplant recipients: comparison antigenemia and molecular biology assays. Liver Transpl 2001; 7: 1004.
26. Gorensek MJ, Carey WD, Vogt D, Goormastic M. A multivariate analysis of risk factors for cytomegalovirus infection in liver-transplant recipients. Gastroenterology 1990; 98: 1326.
27. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis. 2003; 187: 1801.
28. Daly JS, Kopasz A, Anandakrishnan R, et al. Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients. Am J Transplant 2002; 2: 955.